EGRX (Eagle Pharmaceuticals) Buyback Yield %: 0.00 (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EGRX Eagle Pharmaceuticals Inc EGRX
16 GF Score
Price $0.75
View Full Analysis

What is Eagle Pharmaceuticals Buyback Yield %?

Eagle Pharmaceuticals EGRX 16 Buyback Yield % is 0.00 as of Sep. 07, 2026. GuruFocus rates EGRX with a GF Score™ of 16/100.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Eagle Pharmaceuticals's current buyback yield was 0.00%.

Eagle Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Eagle Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals Buyback Yield % Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 2.11 5.46 3.19 4.71

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EGRX vs IXHL, RMTI, CHHE: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eagle Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Buyback Yield % falls into.


EGRX
16GF Score
Eagle Pharmaceuticals Inc EGRX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eagle Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Eagle Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-18.004 + 0) / 381.88995
=4.71%

Eagle Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-9.951 + 0) / 255.7332
=3.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Eagle Pharmaceuticals (EGRX) has a Buyback Yield % of 0.00 as of Sep. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Eagle Pharmaceuticals and its competitors.
Is Eagle Pharmaceuticals' Buyback Yield % too high?
Eagle Pharmaceuticals' current Buyback Yield % is 0.00. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' Buyback Yield % compare to IXHL and RMTI?
Eagle Pharmaceuticals' Buyback Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Eagle Pharmaceuticals and its competitors. Eagle Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current Buyback Yield % is 0.00 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eagle Pharmaceuticals Business Description

Address 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score

Get the complete analysis for EGRX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price